Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The antibody was designed and developed at Abzena’s Cambridge, UK,
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
The event will be attended by 35,000+ industry professionals
Subscribe To Our Newsletter & Stay Updated